Xbrane Biopharma AB
F:7XB

Watchlist Manager
Xbrane Biopharma AB Logo
Xbrane Biopharma AB
F:7XB
Watchlist
Price: 1.037 EUR 10.26% Market Closed
Market Cap: 30.3m EUR

Wall Street
Price Targets

7XB Price Targets Summary
Xbrane Biopharma AB

Wall Street analysts forecast 7XB stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for 7XB is 5.645 EUR with a low forecast of 5.59 EUR and a high forecast of 5.812 EUR.

Lowest
Price Target
5.59 EUR
439% Upside
Average
Price Target
5.645 EUR
444% Upside
Highest
Price Target
5.812 EUR
460% Upside
Xbrane Biopharma AB Competitors:
Price Targets
ARX
Aroa Biosurgery Ltd
13% Upside
IVVD
Invivyd Inc
220% Upside
SYNACT
SynAct Pharma AB
12% Upside
XLO
Xilio Therapeutics Inc
211% Upside
7774
Japan Tissue Engineering Co Ltd
128% Upside
FYB
Formycon AG
94% Upside
005690
Pharmicell Co Ltd
24% Upside
MRSN
Mersana Therapeutics Inc
16% Upside

Revenue
Forecast

Revenue Estimate
Xbrane Biopharma AB

For the last 11 years the compound annual growth rate for Xbrane Biopharma AB's revenue is 88%. The projected CAGR for the next 3 years is 38%.

88%
Past Growth
38%
Estimated Growth
Estimates Accuracy
-19%
Average Miss

Operating Income
Forecast

Operating Income Estimate
Xbrane Biopharma AB

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
5%
Average Beat

Net Income
Forecast

Net Income Estimate
Xbrane Biopharma AB

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-91%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is 7XB's stock price target?
Price Target
5.645 EUR

According to Wall Street analysts, the average 1-year price target for 7XB is 5.645 EUR with a low forecast of 5.59 EUR and a high forecast of 5.812 EUR.

What is Xbrane Biopharma AB's Revenue forecast?
Projected CAGR
38%

For the last 11 years the compound annual growth rate for Xbrane Biopharma AB's revenue is 88%. The projected CAGR for the next 3 years is 38%.

Back to Top